soul trial oral semaglutide cardiovascular outcomes 2024 results nejm and in Type 2 Diabetes The SOUL Study - by

Diabetes 54 , 5162 (2005)

No causal relationship has been established in humans to date, and population-level data from large GLP-1 user cohorts have not shown a clear increase in MTC incidence.[5] That said, there are defined contraindications: GLP-1 therapy is not appropriate for patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2 syndrome)

You can choose one as per your taste and preference

A standard clinical dose starts at 2mg once weekly, escalating to 4mg, 8mg, and 12mg every 4 weeks per Phase 2 data

The peptide safety and risks guide provides a thorough overview of what is known and where knowledge gaps remain

Parsons LH, Hurd YL